Why I’m Eyeing Prices, Biotech and AI in Q3
As the second quarter skims some froth off the technology trade, let’s see why these three areas are key to watch in Q3.
Going Back to the Well in a Sector That’s Working
After years of underperformance, biotech is finally catching a nice bid. Here’s my strategy on a name showing promise.
This Biotech Could Become a ‘Sleeper’ Hit
Let’s look at this rising biopharma name working on several neurological condition treatments.